Home | About Us | Resources | Advertisement 




New Hair Loss Treatment


September 18-2014 - In four months, Ruxolitinib a drug already used in cancer treatment, can regrow hair of patients with hair loss (alopecia). Is this finally a new treatment against baldness?   

All over the world men and women are looking for an effective hair loss treatment. Scientists are also working behind the scene 


ALOPECIA patients can now have their beautiful hair back in less than 4 months.  Researchers at Columbia University seem to have found the formula. Almost by accident, they discovered that the anti-cancer drug ruxolitinib (used to treat myelofibrosis, a condition in which the bone marrow is replaced by scar tissue and causes decreased blood cell production) had allowed three patients with alopecia areata to regain their hair after only 5 months of treatment. This discovery was published in the Natural Medicine Journal Sunday, August 17.   

 areata is a form of baldness that causes massive and rapid hair loss. This fairly common disease is due to a disorder of the immune system in which the cells of the scalp, hair follicles, which are responsible for hair growth, would lead the immune system to no longer recognize its cells and therefore attack them. When that happens, the hair stops growing and then fall. But scientists have discover an unexpected hair loss treatment.   


Ruxolitinib is a form of oral receptor tyrosine kinase inhibitor treatment which works as an immune regulatory molecule. It proved capable of blocking the action of immune cells and thus stops the abnormal attacks against the hair follicles. In five months the three patients had indeed regrown their hair back.  

Changes in the hair of the three patients treated with the chemotherapy drug are pretty impressive. It awakens necessarily hope for many people who start losing their hair. Unfortunately, there is very little chance that the treatment is effective against the most common form of baldness. It is also characterized by a significant loss of hair on the top of the skull and the temporal lobes, but it is due to an excess of male hormones which is hereditary and not about the immune system. This hormone excess shortens the life cycle of the hair follicles, thus leading to hair loss or baldness.  


Those who suffer from this type of hair loss will not, therefore, profit from this breakthrough; they will have to receive another hair loss treatment, which may not be with a chemotherapy drug.  


Another treatment showed similar results on patients with alopecia areata. This time, researchers at Yale University ‚Äčtested a drug called XELJANZ® (tofacitinib citrate) which is usually prescribed to treat another autoimmune disease called rheumatoid arthritis, a chronic inflammatory disorder that typically affects the small joints in your hands and feet. Again, hair regrowth was rapid and massive, but no guarantee can be given about the possible effectiveness for common baldness.